Myriad Genetics (FRA:MYD) Other Long Term Assets: €4.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MYD Myriad Genetics Inc FRA:MYD
42 GF Score
Price €2.90
GF Value €9.49
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Myriad Genetics Other Long Term Assets?

Myriad Genetics FRA:MYD +1.90% 42 Other Long Term Assets is €4.3 Mil as of Jun. 2026. GuruFocus rates FRA:MYD with a GF Score™ of 42/100 and a GF Value™ of €9.49 (Possible Value Trap). The stock has 3 warning signs investors should review.

Myriad Genetics's other long-term assets for the quarter that ended in Jun. 2026 was €4.3 Mil.

Myriad Genetics's quarterly other long-term assets increased from Dec. 2025 (€4.8 Mil) to Mar. 2026 (€4.8 Mil) but then stayed the same from Mar. 2026 (€4.8 Mil) to Jun. 2026 (€4.3 Mil).

Myriad Genetics's annual other long-term assets declined from Dec. 2023 (€14.1 Mil) to Dec. 2024 (€8.1 Mil) and declined from Dec. 2024 (€8.1 Mil) to Dec. 2025 (€4.8 Mil).

Myriad Genetics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Other Long Term Assets Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.34 14.63 14.12 8.12 4.78

Myriad Genetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.68 5.62 4.78 4.84 4.25
FRA:MYD
42GF Score
Myriad Genetics Inc FRA:MYD
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €4.3 Mil mean?
Myriad Genetics (FRA:MYD) has a Other Long Term Assets of €4.3 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Other Long Term Assets too high?
Myriad Genetics' current Other Long Term Assets is €4.3 Mil. Overall, Myriad Genetics has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Other Long Term Assets compare to BDSX and XGN?
Myriad Genetics' Other Long Term Assets of €4.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Diagnostics & Research company?
A good Other Long Term Assets depends on the Medical Diagnostics & Research industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Other Long Term Assets is €4.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (FRA:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €9.49, compared to a current price of €2.90 — trading 69.5% below its estimated fair value. The current Other Long Term Assets is €4.3 Mil. Myriad Genetics' overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Myriad Genetics (FRA:MYD), the current Other Long Term Assets is €4.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (FRA:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €2.90 is trading 69.5% below its estimated GF Value™ of €9.49. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for FRA:MYD:

  • Other Long Term Assets: €4.3 Mil
  • GF Value™: €9.49 vs. price of €2.90 (69.5% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the FRA:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UK
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
42GF Score

Get the complete analysis for FRA:MYD

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€9.49
GF Value